Adverse drug reactions of PD-1/PD-L1 inhibitors were monitored in 31 patients with liver cancer
Objective In order to monitor the adverse reactions and safety issues of PD-1/PD-L1 inhibitors in patients with liver cancer,and provide reference for preventing and timely handling of related serious adverse reactions and clinical safe and rational drug use,a retrospective analysis of immune-related adverse reactions was conducted jointly with Zhuhai Sentinel Hospital,based on the evidence-based analysis of literature data and the optimization design of research protocols.Methods The clinical data of 31 patients with liver cancer treated with PD-1/PD-L1 inhibitor from January 1,2019 to December 31,2023 in Zhuhai ADR/ADE spontaneous reporting system database,were analyzed retrospectively.Descriptive methods were used to analyze the reporting information,demographic characteristics,medication status and clinical manifestations of patients.Results The main clinical manifestations of the use of PD-1/PD-L1 inhibitors in patients with hepatocellular carcinoma are myelosuppression,pruritus,and rash.There were 21 cases of severe report(67.74%)and 10 cases of general report(32.26%).Among the cases of adverse reactions,the most common adverse reaction was bone marrow suppression,with a total of 6 cases,accounting for 19.35%.Adverse reactions could involve multiple systems of the body,among which skin and appendage damage was the most common,with 14 cases(45.16%).Conclusion In the process of treating liver cancer patients with PD-1/PD-L1 inhibitors,it is important to develop individualized drug treatment plans based on the patient's age and gender,and to conduct follow-up and monitoring to prevent potential ADRs in a timely manner,which plays a crucial role in improving the clinical safety of drug use and improving the prognosis of these patients.
PD-1/PD-L1 inhibitorsLiver cancer patientsAdverse reactions
万方数据
维普
